Quest Diagnostics Incorporated

Valuation Analysis

About the Company

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other

Quest Diagnostics Incorporated Stock at a Glance

Quest Diagnostics Incorporated (DGX) is currently trading at $203.06 with a market capitalization of $22.5B. The trailing P/E ratio stands at 22.41x, with a forward P/E of 17.4x. The 52-week range spans from $164.65 to $213.50; the current price is 4.9% below the yearly high. Year-over-year revenue growth stands at +9.2%. The net profit margin stands at 9.08%.

💰 Dividend

Quest Diagnostics Incorporated pays an annual dividend of $3.44 per share, representing a yield of 1.69%. The payout ratio stands at 36.02%.

📊 Analyst Rating

16 analysts rate Quest Diagnostics Incorporated (DGX) on consensus: Buy. The average price target is $223.44, implying +10.04% from the current price. Analyst price targets range from $184.00 to $245.00.

Quest Diagnostics Incorporated: The Investment Case in Detail

Quest Diagnostics Incorporated (DGX) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

What to Watch Next

• The forward P/E of 17.4x is meaningfully below the trailing 22.41x — analysts expect earnings to step up; the next earnings release is the test.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Quest Diagnostics Incorporated?

Compare top-rated brokers — low fees, trusted providers, fully regulated.